Address: 191 Silom Road, Kwaeng Silom
17th Floor, Room No. 4, Silom Complex Building,
Khet Bangrak, Bangkok 10500
Tel: +662 686 2600
Quintiles is the world’s largest biopharmaceutical services company (2011 net revenue exceeding $3 billion) and the only one offering fully integrated clinical, commercial, consulting and capital solutions worldwide. Quintiles has 25,000 employees and offices in 60 countries.
Quintiles helps biopharma companies navigate the New Health and increase their probability of success. The industry’s challenges include declining R&D productivity; lower returns on marketing and sales; unpredictability in clinical and commercial outcomes; and the “patent cliff” – an estimated $128 billion of branded revenues that have or will lose patent protection between 2009 and 2014.
To succeed, companies must increase speed to market, maximize productivity, improve quality and deliver more value to all healthcare stakeholders. To achieve this transformation, Quintiles provides:
Clinical Development Services aimed at bringing safe, new medicines and devices to patients in need. This group is transforming clinical research to improve productivity, delivery and quality by:
Providing streamlined end-to-end solutions across the drug development lifecycle.
Using sophisticated data analytics to design and execute more effective trials.
Improving study monitoring using data analytics, study indicators and on-site/centralized monitors.
Deploying innovative platforms, such as Quintiles Infosario™, that integrate data, systems and processes to increase clinical development transparency and productivity.
Offering innovative business models, including co-development and outcomes-based models.
Services within Clinical include:
Integrated Site Services to access patients and sites, accelerating recruitment and database lock.
Phase I/IIa trial services for early phase human drug development.
Phase IIb-IIIa trial services focused on regulatory approval.
The full suite of integrated clinical trial services to support Phase I-IIIa trials, including:
GLP bioanalytical and global central laboratories.
Cardiac safety services (ECG).
Lifecycle safety services focused on quantifying the benefit-risk-value profile of a product.
Functional service provider (FSP) solutions.
Real-world and late phase solutions focused on monitoring and evaluating product safety and benefit-risk; demonstrating efficacy and effectiveness; gaining market access; expanding labeling; understanding the natural history of disease; and improving quality of care.
Evidence development solutions, including interventional IIIb/IV trials; observational research and registries; electronic health records and database studies.
The full suite of integrated study services and technologies to support real-world and late phase programs, including epidemiology; biostatistics; data management; project management; monitoring; site recruitment and management; data assets; electronic data capture, including the patented Outcome System®; and integration of electronic medical and electronic health records.
Commercial solutions (formerly known as Innovex) to help customers identify the optimal value of their drug or biologic; launch and promote treatments; and demonstrate the value of their products over time by engaging with patients and driving adherence. This group helps customers optimize commercial value to all stakeholders across the entire brand lifecycle.
Quintiles has the world’s largest Commercial solutions organization dedicated to the launch and marketing of products on a country-specific, regional or global basis, with 10,000+ field professionals in more than 30 countries addressing physician and patient needs.
Our Commercial solutions area includes:
Sales Solutions, including the recruitment, training and deployment of customer-managed primary and secondary sales teams; health management services; and vacancy management.
Medical Communications to promote physician education and communications programs, including symposia, exhibition support at major scientific congresses, advisory boards and publication planning.
Brand Solutions that leverage Quintiles’ extensive Commercial capabilities together with marketing management expertise, to take complete or partial responsibility for a brand.
Product Solutions that leverage Quintiles’ insight to help achieve a commercially-guided clinical strategy for both products and portfolios, helping to ensure faster market access and sustained commercial success.
Patient-Centric Services that employ an integrated, closed–loop approach to patient acquisition, adherence and retention to build brand value.
Consulting to help companies maximize potential and minimize risk from discovery through development and commercialization. With full-time consultants in the U.S. and Europe, this group provides strategic, operational and technical advice through the following practice areas:
Product Development and Commercialization.
Regulatory and Quality.
Patient Data Analytics
Capital solutions to help customers achieve strategic goals through custom-tailored risk-based alliances that address their complex strategic and financial needs. This group has leveraged intellectual and human capital, as well as financial resources, to secure more than $2.4 billion in investment commitments for 80+ alliances. Each alliance is custom-tailored but models include:
Investment alliances/structured finance: Underwrite and structure risk-based investments, including due diligence.
Strategic resourcing: Non-traditional service partnerships that meet specific needs and goals.
Emerging companies: Meet unique needs of these customers while providing access to global resources and markets.
Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia’s National…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma,…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Thailand is available for download…
Shinsuke Yuasa, president of Thai Otsuka discusses the importance of Thailand for Otsuka as its first overseas…
Thailand country managers from three of the world’s largest medtech firms outline the level of innovation they…
Nico Form-Zuellig, general manager of Interthai Pharmaceutical Manufacturing, shares his thoughts on the Thai…
Philippe Pedeboscq, managing director of Siemens Healthineers, shares his impressions after taking the lead of the…
Every generation of Novo Nordisk’s insulin portfolio is currently on the Thai Market and the affiliate is one of…
Nares Damrongchai has been the CEO of the Thailand Center of Excellence for Life Science (TCELS) since its…
Rajan Kalidindi, Country Manager for GE Healthcare Thailand, elaborates on the innovative solutions which drive…
The Pharmaceutical Research and Manufacturers Association (PReMA) has been a key stakeholder in promoting the value…